Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care01:30

Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care

A healthcare provider can diagnose a urinary tract infection (UTI) through several methods:Medical History and Symptoms: The provider will take a detailed medical history and ask about symptoms such as frequent urination, burning sensation during urination, and lower abdominal pain.Urinalysis: A clean-catch urine sample is collected in a sterile container and tested for the presence of bacteria, white blood cells (leukocytes), nitrites, blood, and protein. The presence of leukocytes and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Physician Payment Incentives and Active Surveillance in Low-Risk Prostate Cancer.

JAMA network open·2025
Same author

The 340B Drug Pricing Program and Management of Advanced Prostate Cancer.

Cancer medicine·2024
Same author

Hospital Quality and Racial Differences in Outcomes After Genitourinary Cancer Surgery.

Cancer medicine·2024
Same author

Commercial Prices and Care for Medicare Beneficiaries With Prostate Cancer.

Urology·2024
Same author

Commercial prices and their influence on urology practices: Prostate cancer care among men with Medicare.

Cancer·2024
Same author

Detection of Germline Variants in Patients With Localized and Metastatic Prostate Cancer Through Guideline-Based Testing.

Urology practice·2024
Same journal

Editorial Comment.

The Journal of urology·2026
Same journal

Editorial Comment.

The Journal of urology·2026
Same journal

Editorial Comment.

The Journal of urology·2026
Same journal

Uro-Science.

The Journal of urology·2026
Same journal

Editorial Comment.

The Journal of urology·2026
Same journal

Editorial Comment.

The Journal of urology·2026
See all related articles

Related Experiment Video

Updated: May 11, 2026

Transperineal Prostate Biopsy Using a Cone-shaped Double-hole Method with Dual-plane Probe Guidance
05:35

Transperineal Prostate Biopsy Using a Cone-shaped Double-hole Method with Dual-plane Probe Guidance

Published on: June 6, 2025

Technology diffusion and diagnostic testing for prostate cancer.

Florian R Schroeck1, Samuel R Kaufman, Bruce L Jacobs

  • 1Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor, Michigan; Division of Urologic Oncology, Department of Urology, University of Michigan, Ann Arbor, Michigan.

The Journal of Urology
|May 15, 2013
PubMed
Summary
This summary is machine-generated.

New technologies in prostate cancer treatment are linked to slightly more prostate-specific antigen testing but do not increase prostate biopsies. This suggests advanced treatments do not accelerate overall diagnostic testing for prostate cancer.

Keywords:
HRRIMRTPSAbiomedical technologyhospital referral regionintensity modulated radiotherapyintensity-modulatedprostateprostate specific antigenprostate-specific antigenprostatic neoplasmsradiotherapy

More Related Videos

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
09:11

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

Related Experiment Videos

Last Updated: May 11, 2026

Transperineal Prostate Biopsy Using a Cone-shaped Double-hole Method with Dual-plane Probe Guidance
05:35

Transperineal Prostate Biopsy Using a Cone-shaped Double-hole Method with Dual-plane Probe Guidance

Published on: June 6, 2025

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
09:11

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

Area of Science:

  • Urology
  • Health Services Research
  • Oncology

Background:

  • The adoption of advanced treatments like robotic prostatectomy and intensity modulated radiotherapy may influence diagnostic testing patterns for prostate cancer.
  • Understanding the relationship between technological advancements and diagnostic procedures is crucial for healthcare planning.

Purpose of the Study:

  • To investigate the association between the regional availability of advanced prostate cancer technologies and the rates of prostate-specific antigen (PSA) testing and prostate biopsy.
  • To determine if increased technology penetration correlates with higher diagnostic testing rates.

Main Methods:

  • A retrospective cohort study analyzed 117,857 men aged 66+ from Medicare beneficiaries in SEER areas (2003-2007).
  • Regional technology penetration was quantified by the number of providers offering robotic prostatectomy or intensity modulated radiotherapy per capita within hospital referral regions.
  • Generalized estimating equations were used to assess the association between technology penetration and PSA testing and biopsy rates.

Main Results:

  • Higher technology penetration was associated with a modest increase in PSA testing rates (442 vs 425/1,000 person-years, p<0.01).
  • No significant difference in prostate biopsy rates was observed with increased technology penetration (10.1 vs 9.9/1,000 person-years, p=0.69).
  • Factors like age, race, and comorbidity had a greater impact on PSA testing rates than technology penetration.

Conclusions:

  • Increased regional availability of advanced prostate cancer technologies is linked to a slight rise in PSA testing but not prostate biopsies.
  • These findings suggest that the adoption of new treatment technologies does not significantly accelerate the rate of diagnostic testing for prostate cancer.
  • Concerns about technology-driven increases in prostate cancer diagnostic workups may be overstated.